Dr. Farkas, who was head of the FDA’s clinical team in the neurology products division, played a large role in the FDA’s review of Eteplirsen. During an FDA advisory meeting in April, Dr. Farkas said he had “strong doubts” about the reliability of Sarepta’s clinical trial data and the drug’s effectiveness, reported STAT.
The FDA deferred its decision on whether to approve the drug in late May after an advisory panel concluded the drug was not effective.
It is not clear when Dr. Farkas left the agency or whether his departure is tied to Sarepta.
“We view [his departure] as a positive signal for Eteplirsen approval,” said Wall Street analyst Michelle Gilson. Cambridge, Mass.-based Sarepta’s shares jumped about 26 percent to $32.45 upon news of Dr. Farkas’ FDA exit.
More articles on supply chain:
FDA approves Medtronic’s drug-coated balloon to treat in-stent restenosis
FDA should remove warning from Pfizer’s drug label, advisory panel says
Allergan to acquire Vitae Pharmaceuticals for $639M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.